Sinovac and swine flu

• Published 20 Aug 2009

The developer and provider of vaccines is benefiting from orders from the Ministry of Health to supply its swine flu and hepatitis A products to high-risk groups.

Over the short term, Sinovac Biotech, a New York AMEX-listed (SVA:AMEX) company, seems set to be a beneficiary of swine flu. As a leading developer and provider of vaccines in China, the company in July received its first order from the Ministry of Health (MOH) to supply its pandemic influenza A/H1N1, swine flu vaccine for high-risk groups such as medical staff and laboratory workers.

China Confidential Funds

China Confidential Funds, a new research service launched by FT China Confidential, is dedicated to illuminating the mainland fund industry. Our team of fund industry experts in Shanghai search out the interesting trends in fund performance, strategy, interactions with overseas funds, regulatory changes, distribution and management. We also use a proprietary system to track the emerging flows of Chinese money. Click here to find out more.

Other Articles on this Issue

• Macro View

  A moment of truth

• Funds Data

  China zeal wavers

• Forbidden City

  Iron and awe

• The Big Call

  A local financial time bomb

• Postcard From No 528

  Wobbling on the liquidity high wire

• Financial China

  Insurance - a structural play

  Ping An - not so tranquil

  China Life - in the balance

• Capital Intensive China

  Developers defy doomsayers

• The Best of Chinese Commentators

  Inflation, inflation, inflation

  Sovereign wealth

• Consumer China

  Pharmaceuticals - a healthy course

  Sinopharm - a new contender

  Simcere – not immune

  Tongrentang – TCM bellwether

• Guest Column

  Bright prospects

• View issue